Clean 12% growth, and the conversion gap underneath it

A dental practice going to market can show clean 12% YoY growth on the financials while still also having 30 to 40% of its diagnosed treatment sitting unscheduled in the PMS. This is where deals get priced sub-optimally, as the buyer is paying a multiple of EBITDA that assumes the current growth rate continues while that growth rate comes from a practice that isn't even converting 30 to 40% of what it already diagnoses.

Thing is, the buyer isn't just paying for the EBITDA, they're paying for a trajectory, and the trajectory they're underwriting is built on top of a broken conversion pattern nobody is quantifying. If the target was growing 12% while leaking a notable amount too, a few things become immediately relevant to the buyer that rarely get quantified pre-close.

First, the growth rate is structurally capped. You can't compound 12% forever on top of a practice that's converting a fraction of what it diagnoses, because the unconverted pile gets bigger every quarter and eventually the capacity to convert it caps out before production does. The buyer underwrote a growth curve that the operational reality of the practice can't actually sustain, and nobody ran the numbers on where the ceiling is.

Second, the conversion pattern itself tells you what you actually bought. A practice leaking 30 to 40% of diagnosed treatment has a specific operational profile, whether it's treatment-plan presentation failing at the front end, no systematic follow-up on accepted plans, a scheduling coordinator who left six months ago and was never replaced, or a provider who doesn't close treatment. The buyer walks in without really knowing which of those they're inheriting, how expensive it is to fix, or whether the seller staying on 12 months post-close helps or hurts.

Third, it directly changes what the real run-rate EBITDA looks like. If you work through the backlog over 18 months, EBITDA steps up meaningfully in years 2 and 3 in a way the model didn't capture. If you can't, year 1 EBITDA comes in below the underwriting number because the growth rate that was baked into projections was riding on conversion weakness that doesn't fix itself under new ownership.

Dental PE has moved from multiple arbitrage to operational execution, and the old diligence stack was built for the world where year 1 operational reality was assumed to work itself out. But over 40 DSOs were brought to market in the past two years and less than 10 closed, all because the operational reality at each tuck-in did not match what was sold and the problems compounded platform-level.

None of this gets properly quantified pre-close because the backlog rarely makes it onto the table. The financial QoE answers what was earned, but the Operational QoE answers what is actually capable of being earned and what happens when a buyer inherits the gap.